The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3
Open accessAbstract
Hdm2 and HdmX coordinately regulate the stability and function of p53. Each is overexpressed in subsets of many different types of malignancy, and most of these subsets maintain wild-type p53. Nutlins, newly discovered small-molecule inhibitors of the Hdm2-p53 interaction, offer a novel strategy for therapy of tumors with wild-type p53. We now show that Nutlin-3 efficiently induces apoptosis and diminishes long-term survival of human fibroblasts transformed in vitro by Hdm2 but not HdmX. The resistance of cells overexpressing HdmX to Nutlin-3 is due to its inability to disrupt the p53-HdmX interaction, resulting in continued suppression of p53 activity. Although HdmX overexpression yielded cells resistant to Nutlin-3, ablation of HdmX expression by short hairpin RNA sensitized tumor cells to Nutlin-3–mediated cell death or arrest. Furthermore, deletion of the COOH-terminal RING finger domain of HdmX completely reversed the resistance to Nutlin-3, probably reflecting the requirement of the RING finger for interaction with Hdm2. Thus, the relative abundance of Hdm2 and HdmX and the specificity of Nutlin-3 for Hdm2 influence the sensitivity of cells to p53-dependent apoptosis or arrest in response to Nutlin-3. Our findings establish Hdm2 and HdmX as independent therapeutic targets with respect to reactivating wild-type p53 as a means for cancer therapy. (Cancer Res 2006; 66(6): 3169-76)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [29]
In the citing paper
“Although nutlin 3a and MI-219 robustly activate p53 in cancer cells with overexpressed MDM2, they do not consistently elicit p53-dependent effects in cancer cells that overexpress MDMX99–102.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [99]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Activation of p53 in response to various intracellular and extracellular stress signals leads to the transcriptional regulation of an ever increasing number of genes important for suppressing tumorigenesis ( 1 ).”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 3×
“The use of Nutlin-3 has worked well in specific tumor cell lines and xenograft tumors, acute myeloid leukemias, and multiple myelomas ( 33 , 45, 46).”
BackgroundInfluentialMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“The importance of Mdm2, the mouse isoform of Hdm2, in regulating p53 is shown by the embryonic lethality of mdm2 deletion (7, 8), which is specific for the loss of Mdm2-mediated p53 inhibition as deletion of both p53 and mdm2 results in viable animals that have an increased frequency of tumors similar to those with p5…”
BackgroundThe p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · cited 2×
“Furthermore, the hdm2 gene is transcriptionally regulated by p53 (20, 21).”
Backgroundp53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“The importance of Mdm2, the mouse isoform of Hdm2, in regulating p53 is shown by the embryonic lethality of mdm2 deletion (7, 8), which is specific for the loss of Mdm2-mediated p53 inhibition as deletion of both p53 and mdm2 results in viable animals that have an increased frequency of tumors similar to those with p5…”
BackgroundRescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1×
“The importance of Mdm2, the mouse isoform of Hdm2, in regulating p53 is shown by the embryonic lethality of mdm2 deletion (7, 8), which is specific for the loss of Mdm2-mediated p53 inhibition as deletion of both p53 and mdm2 results in viable animals that have an increased frequency of tumors similar to those with p5…”
BackgroundThe codon 72 polymorphic variants of p53 have markedly different apoptotic potential
Dumont, P., Leu, J. I.-J., Della Pietra, A. C., George, D. L., & Murphy, M. (2003) · Nature Genetics · doi:10.1038/ng1093 · Cited by 1,273
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270 · cited 1×
“Importantly, much like Hdm2-p53 complexes, HdmX-p53 complexes can be disrupted by phosphorylation in response to DNA damage (22, 23).”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“In addition to activating wild-type p53, the PRIMA-1 compound was also found to structurally alter tumor-derived p53 mutants and restore their wild-type conformation, inducing apoptosis in a series of cancer cell lines (34).”
Background
Cited by
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
“Overexpression of a RING finger domain–deleted MDMX mutant in transformed fibroblasts did not provide protection to cells against Nutlin-3, indicating that the MDM2-MDMX interaction is required for protective function of MDMX, probably for the MDM2-mediated ubiquitinization of MDMX (70).”
BackgroundInfluential
Metadata
- Authors
- Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W.
- Affiliations
- Cleveland Clinic (US)
- Case Comprehensive Cancer Center (US)
- Venue
- Cancer Research
- Published
- 2006-03-15
- Volume
- 66
- Issue
- 6
- Pages
- 3169-3176
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2106718280
- Cited by
- 189
- References
- 46
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 1 · 2023: 7 · 2022: 5 · 2021: 5 · 2020: 5 · 2019: 2 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 9 · 2014: 9 · 2013: 13 · 2012: 14
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Case Comprehensive Cancer Center, Case Western Reserve University (P30CA43703)
- National Heart, Lung, and Blood Institute (F32HL072661)
- National Cancer Institute (P-30 CA43703, R01CA109262, P30CA043703)
- National Institute of General Medical Sciences (R01GM049345)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- HDMX, MDM2, Nutlin-3, p53, p53-MDM2 interaction, p53 reactivation, apoptosis, RING domain, shRNA, transformed fibroblasts, drug resistance, cancer therapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Cell Transformation, Neoplastic, Colonic Neoplasms, Doxorubicin, Drug Screening Assays, Antitumor, Drug Synergism, Fibroblasts, Humans, Imidazoles, Nuclear Proteins, Piperazines, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Protein Structure, Tertiary, Cell Cycle Proteins, RNA, Small Interfering, HCT116 Cells, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3832
- The paper
- Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006). Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.